201. CDKN3 mRNA as a Biomarker for Survival and Therapeutic Target in Cervical Cancer.
- Author
-
Barrón EV, Roman-Bassaure E, Sánchez-Sandoval AL, Espinosa AM, Guardado-Estrada M, Medina I, Juárez E, Alfaro A, Bermúdez M, Zamora R, García-Ruiz C, Gomora JC, Kofman S, Pérez-Armendariz EM, and Berumen J
- Subjects
- Base Sequence, Carcinogenesis, Cell Movement, Cell Proliferation, Down-Regulation, Female, Gene Expression Regulation, Neoplastic, HeLa Cells, Humans, Middle Aged, Neoplasm Invasiveness, Neoplasm Staging, Papillomaviridae physiology, RNA, Messenger genetics, RNA, Messenger metabolism, RNA, Small Interfering genetics, Survival Analysis, Uterine Cervical Neoplasms pathology, Uterine Cervical Neoplasms virology, Biomarkers, Tumor genetics, Cyclin-Dependent Kinase Inhibitor Proteins genetics, Cyclin-Dependent Kinase Inhibitor Proteins metabolism, Dual-Specificity Phosphatases genetics, Dual-Specificity Phosphatases metabolism, Molecular Targeted Therapy, Uterine Cervical Neoplasms drug therapy, Uterine Cervical Neoplasms genetics
- Abstract
The cyclin-dependent kinase inhibitor 3 (CDKN3) gene, involved in mitosis, is upregulated in cervical cancer (CC). We investigated CDKN3 mRNA as a survival biomarker and potential therapeutic target for CC. CDKN3 mRNA was measured in 134 CC and 25 controls by quantitative PCR. A 5-year survival study was conducted in 121 of these CC patients. Furthermore, CDKN3-specific siRNAs were used to investigate whether CDKN3 is involved in proliferation, migration, and invasion in CC-derived cell lines (SiHa, CaSki, HeLa). CDKN3 mRNA was on average 6.4-fold higher in tumors than in controls (p = 8 x 10-6, Mann-Whitney). A total of 68.2% of CC patients over expressing CDKN3 gene (fold change ≥ 17) died within two years of diagnosis, independent of the clinical stage and HPV type (Hazard Ratio = 5.0, 95% CI: 2.5-10, p = 3.3 x 10-6, Cox proportional-hazards regression). In contrast, only 19.2% of the patients with lower CDKN3 expression died in the same period. In vitro inactivation of CDKN3 decreased cell proliferation on average 67%, although it had no effect on cell migration and invasion. CDKN3 mRNA may be a good survival biomarker and potential therapeutic target in CC.
- Published
- 2015
- Full Text
- View/download PDF